Symbols / ATHE Stock $4.12 +1.48% Alterity Therapeutics Limited

Healthcare • Biotechnology • Australia • NCM
ATHE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David A. Stamler M.D.
Exch · Country NCM · Australia
Market Cap 77.91M
Enterprise Value 44.76B
Income -14.59M
Sales 6.64M
FCF (ttm) -10.61M
Book/sh 2.14
Cash/sh 0.01
Employees 9
Insider 10d —
IPO Sep 29, 2003
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.49
PEG —
P/S 11.74
P/B 1.93
P/C —
EV/EBITDA -2,550.20
EV/Sales 6,744.24
Quick Ratio 21.68
Current Ratio 21.98
Debt/Eq 0.18
LT Debt/Eq —
EPS (ttm) -0.52
EPS next Y -1.18
EPS Growth —
Revenue Growth 74.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2015-08-25
Earnings (prior) 2015-08-25
ROA -32.54%
ROE -47.02%
ROIC —
Gross Margin 97.55%
Oper. Margin -3.73%
Profit Margin -219.85%
Shs Outstand 18.13M
Shs Float 8.32B
Insider Own 0.00%
Instit Own 1.78%
Short Float 0.05%
Short Ratio 0.26
Short Interest 8.05K
52W High 7.00
vs 52W High -41.14%
52W Low 2.66
vs 52W Low 54.89%
Beta 0.00
Impl. Vol. —
Rel Volume 1.04
Avg Volume 20.03K
Volume 20.91K
Target (mean) $12.00
Tgt Median $12.00
Tgt Low $12.00
Tgt High $12.00
# Analysts 1
Recom None
Prev Close $4.06
Price $4.12
Change 1.48%
About

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.00
Mean price target
2. Current target
$4.12
Latest analyst target
3. DCF / Fair value
$-10.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.12
Low
$12.00
High
$12.00
Mean
$12.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-17 init Canaccord Genuity — → Speculative Buy —
2025-01-30 main Maxim Group Buy → Buy $12
2024-12-12 init Maxim Group — → Buy $8
2024-03-07 reit Benchmark Speculative Buy → Speculative Buy $4
2023-06-05 main Ladenburg Thalmann Buy → Buy $10
News
RSS: Latest ATHE news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
12.33
-36.43%
19.40
+35.04%
14.37
-5.08%
15.14
Research And Development
14.40
-22.74%
18.64
+41.26%
13.20
-10.49%
14.75
Selling General And Administration
5.34
+15.55%
4.62
-6.65%
4.95
-9.26%
5.46
General And Administrative Expense
5.34
+15.55%
4.62
-6.65%
4.95
-9.26%
5.46
Salaries And Wages
2.03
+44.98%
1.40
-26.16%
1.89
-14.41%
2.21
Other Gand A
2.77
+8.52%
2.55
+12.32%
2.27
-9.62%
2.51
Other Operating Expenses
-2.12
-40484.36%
0.01
-80.81%
0.03
+106.03%
-0.45
Total Expenses
12.33
-36.43%
19.40
+35.04%
14.37
-5.08%
15.14
Operating Income
-12.33
+36.43%
-19.40
-35.04%
-14.37
+5.08%
-15.14
EBITDA
-12.19
+36.67%
-19.25
-34.97%
-14.27
+5.42%
-15.08
Normalized EBITDA
-12.13
+37.86%
-19.52
-28.39%
-15.20
+14.63%
-17.81
Reconciled Depreciation
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
EBIT
-12.33
+36.43%
-19.40
-35.04%
-14.37
+5.08%
-15.14
Total Unusual Items
-0.07
-125.70%
0.26
-72.06%
0.93
-65.66%
2.72
Total Unusual Items Excluding Goodwill
-0.07
-125.70%
0.26
-72.06%
0.93
-65.66%
2.72
Net Income
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Pretax Income
-12.08
+36.68%
-19.08
-39.23%
-13.70
-7.24%
-12.78
Net Non Operating Interest Income Expense
0.45
+66.27%
0.27
+1533.12%
0.02
+556.39%
0.00
Net Interest Income
0.45
+66.27%
0.27
+1533.12%
0.02
+556.39%
0.00
Interest Income Non Operating
0.45
+66.27%
0.27
+1533.12%
0.02
+556.39%
0.00
Interest Income
0.45
+66.27%
0.27
+1533.12%
0.02
+556.39%
0.00
Other Income Expense
-0.19
-440.36%
0.06
-91.30%
0.65
-72.44%
2.36
Other Non Operating Income Expenses
-0.13
+38.78%
-0.20
+28.22%
-0.29
+21.83%
-0.36
Gain On Sale Of Security
-0.07
-125.70%
0.26
-72.06%
0.93
-65.66%
2.72
Tax Provision
0.07
+47.66%
0.05
-55.88%
0.10
+49.21%
0.07
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.02
-125.70%
0.08
-72.06%
0.28
-65.66%
0.82
Net Income Including Noncontrolling Interests
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Net Income From Continuing Operation Net Minority Interest
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Net Income From Continuing And Discontinued Operation
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Net Income Continuous Operations
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Normalized Income
-12.10
+37.32%
-19.31
-33.51%
-14.46
+1.98%
-14.75
Net Income Common Stockholders
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Diluted EPS
-1.14
+63.46%
-3.12
-447.37%
-0.57
+82.08%
-3.18
Basic EPS
-1.14
+63.46%
-3.12
-447.37%
-0.57
+82.08%
-3.18
Basic Average Shares
10.66
+75.31%
6.08
-74.95%
24.28
+505.45%
4.01
Diluted Average Shares
10.66
+75.31%
6.08
-74.95%
24.28
+505.45%
4.01
Diluted NI Availto Com Stockholders
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Depreciation Amortization Depletion Income Statement
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
Depreciation And Amortization In Income Statement
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
Depreciation Income Statement
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
Insurance And Claims
0.55
-18.75%
0.68
-6.31%
0.72
+10.02%
0.66
Other Taxes
-5.44
-35.32%
-4.02
-2.68%
-3.91
+16.17%
-4.67
Rent And Landing Fees
—
—
0.07
-13.48%
0.08
Rent Expense Supplemental
—
—
0.07
-13.48%
0.08
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
46.03
+139.42%
19.22
-29.63%
27.32
-33.96%
41.36
Current Assets
45.87
+140.96%
19.04
-29.62%
27.05
-34.26%
41.14
Cash Cash Equivalents And Short Term Investments
40.66
+221.69%
12.64
-19.87%
15.77
-54.68%
34.81
Cash And Cash Equivalents
33.16
+162.35%
12.64
-19.87%
15.77
-54.68%
34.81
Other Short Term Investments
7.50
—
—
—
Receivables
3.94
-2.57%
4.04
-53.36%
8.67
+83.39%
4.73
Accounts Receivable
—
0.00
-100.00%
0.07
0.00
Taxes Receivable
3.94
-2.57%
4.04
-53.00%
8.60
+81.99%
4.73
Accrued Interest Receivable
0.00
-100.00%
0.00
-76.07%
0.00
+3544.44%
0.00
Prepaid Assets
1.23
-46.75%
2.32
-9.88%
2.57
+60.42%
1.60
Other Current Assets
0.04
+2.82%
0.04
+2.27%
0.04
+288.62%
0.01
Total Non Current Assets
0.16
-16.97%
0.19
-30.49%
0.27
+23.04%
0.22
Net PPE
0.16
-16.97%
0.19
-30.49%
0.27
+23.04%
0.22
Gross PPE
0.16
-16.97%
0.19
-74.36%
0.73
-0.58%
0.73
Accumulated Depreciation
—
-0.43
+6.03%
-0.46
+10.61%
-0.51
Other Properties
0.16
-16.97%
0.19
-74.36%
0.73
-0.58%
0.73
Total Liabilities Net Minority Interest
3.62
-33.22%
5.43
+20.44%
4.50
-23.57%
5.89
Current Liabilities
3.53
-34.22%
5.37
+22.63%
4.38
-24.71%
5.82
Payables And Accrued Expenses
2.59
-44.09%
4.64
+30.75%
3.55
-30.57%
5.11
Payables
0.57
-6.17%
0.61
-65.60%
1.78
-65.18%
5.11
Accounts Payable
0.54
-7.38%
0.58
-66.14%
1.72
-66.22%
5.08
Other Payable
0.02
+33.41%
0.01
-57.45%
0.03
-41.14%
0.06
Current Accrued Expenses
2.02
-49.86%
4.02
+127.67%
1.77
-25.09%
2.36
Employee Benefits
—
0.00
-100.00%
0.02
+41.81%
0.01
Pensionand Other Post Retirement Benefit Plans Current
0.88
+65.05%
0.53
-27.22%
0.73
+11.11%
0.66
Total Tax Payable
0.02
+1.78%
0.02
-42.73%
0.03
+3.74%
0.03
Current Debt And Capital Lease Obligation
0.07
-37.54%
0.11
-0.04%
0.11
+85.97%
0.06
Current Capital Lease Obligation
0.07
-37.54%
0.11
-0.04%
0.11
+85.97%
0.06
Other Current Liabilities
0.00
-99.86%
0.10
—
-0.03
Total Non Current Liabilities Net Minority Interest
0.09
+70.56%
0.05
-57.69%
0.12
+66.70%
0.07
Long Term Debt And Capital Lease Obligation
0.09
+70.56%
0.05
-49.70%
0.10
+72.42%
0.06
Long Term Capital Lease Obligation
0.09
+70.56%
0.05
-49.70%
0.10
+72.42%
0.06
Non Current Pension And Other Postretirement Benefit Plans
—
0.00
-100.00%
0.02
—
Stockholders Equity
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Common Stock Equity
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Capital Stock
262.95
+17.83%
223.15
+4.29%
213.97
+0.09%
213.79
Common Stock
262.95
+17.83%
223.15
+4.29%
213.97
+0.09%
213.79
Share Issued
9,127.37
+74.02%
5,245.12
+114.97%
2,439.90
+1.37%
2,406.87
Ordinary Shares Number
9,127.37
+74.02%
5,245.12
+114.97%
2,439.90
+1.37%
2,406.87
Retained Earnings
-225.89
-5.48%
-214.16
-9.75%
-195.13
-7.28%
-181.88
Gains Losses Not Affecting Retained Earnings
—
—
—
3.57
Total Equity Gross Minority Interest
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Total Capitalization
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Working Capital
42.34
+209.86%
13.66
-39.72%
22.67
-35.83%
35.32
Invested Capital
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Total Debt
0.16
-2.26%
0.16
-24.40%
0.21
+79.07%
0.12
Capital Lease Obligations
0.16
-2.26%
0.16
-24.40%
0.21
+79.07%
0.12
Net Tangible Assets
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Tangible Book Value
42.40
+207.31%
13.80
-39.52%
22.81
-35.68%
35.47
Other Equity Interest
5.34
+11.15%
4.81
+20.99%
3.97
+11.40%
3.57
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-11.45
+9.16%
-12.61
+37.08%
-20.04
-62.40%
-12.34
Cash Flow From Continuing Operating Activities
-11.45
+9.16%
-12.61
+37.08%
-20.04
-62.40%
-12.34
Net Income From Continuing Operations
-12.15
+36.48%
-19.12
-38.51%
-13.81
-7.47%
-12.85
Depreciation Amortization Depletion
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
Depreciation
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
Depreciation And Amortization
0.14
-5.30%
0.15
+44.26%
0.10
+88.63%
0.05
Other Non Cash Items
0.45
—
—
0.00
Stock Based Compensation
0.98
+11.11%
0.88
-8.75%
0.97
-35.82%
1.51
Asset Impairment Charge
0.00
0.00
-100.00%
0.01
0.00
Operating Gains Losses
-0.26
+0.66%
-0.26
+71.54%
-0.92
+67.39%
-2.81
Net Foreign Currency Exchange Gain Loss
-0.26
+0.66%
-0.26
+71.54%
-0.92
+67.39%
-2.81
Change In Working Capital
-0.61
-110.67%
5.75
+189.96%
-6.39
-462.49%
1.76
Change In Receivables
0.10
-97.75%
4.62
+217.35%
-3.94
-780.16%
-0.45
Change In Payables And Accrued Expense
-2.04
-285.48%
1.10
+170.62%
-1.56
-159.94%
2.60
Change In Payable
-2.04
-285.48%
1.10
+170.62%
-1.56
-159.94%
2.60
Change In Other Working Capital
0.35
+258.35%
-0.22
-377.06%
0.08
-35.97%
0.12
Change In Other Current Assets
1.08
+327.44%
0.25
+126.13%
-0.97
-87.57%
-0.52
Change In Other Current Liabilities
-0.10
-736.71%
-0.01
0.00
0.00
Investing Cash Flow
-7.50
-130973.05%
-0.01
+84.31%
-0.04
+59.10%
-0.09
Cash Flow From Continuing Investing Activities
-7.50
-130973.05%
-0.01
+84.31%
-0.04
+59.10%
-0.09
Net PPE Purchase And Sale
0.00
+100.00%
-0.01
+21.73%
-0.01
+91.80%
-0.09
Purchase Of PPE
0.00
+100.00%
-0.01
+21.73%
-0.01
+91.80%
-0.09
Capital Expenditure
—
-0.01
+21.73%
-0.01
+91.80%
-0.09
Net Investment Purchase And Sale
-7.50
0.00
0.00
—
Purchase Of Investment
-7.50
0.00
0.00
—
Net Other Investing Changes
—
—
-0.03
—
Financing Cash Flow
39.67
+330.43%
9.22
+7312.17%
0.12
-99.24%
16.30
Cash Flow From Continuing Financing Activities
39.67
+330.43%
9.22
+7312.17%
0.12
-99.24%
16.30
Net Issuance Payments Of Debt
-0.13
-1125.62%
-0.01
+82.69%
-0.06
-73.62%
-0.03
Repayment Of Debt
-0.13
-1125.62%
-0.01
+82.69%
-0.06
-73.62%
-0.03
Long Term Debt Payments
-0.13
-1125.62%
-0.01
+82.69%
-0.06
-73.62%
-0.03
Net Long Term Debt Issuance
-0.13
-1125.62%
-0.01
+82.69%
-0.06
-73.62%
-0.03
Net Common Stock Issuance
42.57
+319.64%
10.14
+3103.50%
0.32
-98.16%
17.18
Net Other Financing Charges
-2.77
-202.19%
-0.92
-593.30%
-0.13
+84.18%
-0.84
Changes In Cash
20.72
+710.21%
-3.40
+82.98%
-19.95
-614.37%
3.88
Effect Of Exchange Rate Changes
-0.20
-176.19%
0.26
-71.54%
0.91
-67.48%
2.81
Beginning Cash Position
12.64
-19.87%
15.77
-54.68%
34.81
+23.80%
28.12
End Cash Position
33.16
+162.35%
12.64
-19.87%
15.77
-54.68%
34.81
Free Cash Flow
-11.45
+9.20%
-12.61
+37.08%
-20.04
-61.29%
-12.43
Cash Flowsfromusedin Operating Activities Direct
-11.45
+9.16%
-12.61
+37.08%
-20.04
-62.40%
-12.34
Classesof Cash Payments
-17.53
+18.29%
-21.45
-7.00%
-20.05
-18.49%
-16.92
Classesof Cash Receiptsfrom Operating Activities
5.63
-34.41%
8.58
—
4.58
Common Stock Issuance
42.57
+319.64%
10.14
+3103.50%
0.32
-98.16%
17.18
Interest Paid Direct
0.00
+100.00%
-0.01
-58.09%
-0.00
-99.78%
-0.00
Interest Received Direct
0.45
+65.86%
0.27
+1603.22%
0.02
+473.43%
0.00
Issuance Of Capital Stock
42.57
+319.64%
10.14
+3103.50%
0.32
-98.16%
17.18
Other Cash Receiptsfrom Operating Activities
—
—
—
0.45
Paymentsto Suppliersfor Goodsand Services
-17.46
+18.39%
-21.39
-7.27%
-19.94
-18.18%
-16.88
Receiptsfrom Government Grants
—
—
0.00
-100.00%
0.45
Taxes Refund Paid Direct
5.56
-34.77%
8.53
+8340.90%
-0.10
-102.53%
4.08
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category